2022
DOI: 10.1016/j.clbc.2021.10.007
|View full text |Cite
|
Sign up to set email alerts
|

The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 118 publications
0
3
0
Order By: Relevance
“…Although most patients with breast cancer are diagnosed with early-stage disease, 6% to 10% initially present with metastatic breast cancer (MBC), and an additional 20% to 30% will later develop MBC ( 1 ). Of these, approximately two thirds have estrogen and/or progesterone receptor–positive, HER2-negative (HR + HER2 − ) disease ( 2 ). The approval of cyclin-dependent kinase (CDK)4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) in 2015 set a new standard of care, eventually displacing ET alone or chemotherapy as the preferred first-line treatment option for most patients ( 3, 4 ).…”
Section: Introductionmentioning
confidence: 99%
“…Although most patients with breast cancer are diagnosed with early-stage disease, 6% to 10% initially present with metastatic breast cancer (MBC), and an additional 20% to 30% will later develop MBC ( 1 ). Of these, approximately two thirds have estrogen and/or progesterone receptor–positive, HER2-negative (HR + HER2 − ) disease ( 2 ). The approval of cyclin-dependent kinase (CDK)4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) in 2015 set a new standard of care, eventually displacing ET alone or chemotherapy as the preferred first-line treatment option for most patients ( 3, 4 ).…”
Section: Introductionmentioning
confidence: 99%
“…Approximately 60%–70% of patients with breast cancer have oestrogen receptor-positive (ER+) and human epidermal growth factor 2-negative (HER2−) tumours [ 1 , 2 ]. Historically, endocrine therapy, either alone or after adjuvant chemotherapy (depending on high-risk clinicopathological factors [eg, large tumour size, high histological grade, and greater extent of lymph node involvement]), has been the treatment option for patients with early-stage disease [ [3] , [4] , [5] ].…”
Section: Introductionmentioning
confidence: 99%
“…This molecular subtype accounts for 60-70% of all MBCs, that are oestrogen-dependent for development and metastasis. A high level of this hormone is a factor inducing the proliferation of cancer cells and inhibiting their apoptosis [2,3]. www.journals.viamedica.pl/medical_research_journal Determination of the expression of receptors, including oestrogen (ER), progesterone (PR) and epidermal growth factor receptor (HER2) is a diagnostic standard, is a predictive and prognostic factor in breast cancer, and enables the selection of optimal therapy.…”
Section: Introductionmentioning
confidence: 99%